TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21434580
Drug: Memantine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (20 mg) with buprenorphine placebo
Study: 21434580
Drug: Buprenorphine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (2 mg) with memantine placebo
Study: 19887810
Drug: Quality of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality of life, coping, global assessments of treatment success
Study: 10770146
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg, in 1 tablet daily (n = 1380)
Study: 3591595
Drug: Terodiline hydrochloride
Normalized name: Terodiline hydrochloride
DrugBank: Terodiline (DB13725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terodiline hydrochloride 24 mg once a day for 4 weeks
Study: 3591595
Drug: Terodiline hydrochloride
Normalized name: Terodiline hydrochloride
DrugBank: Terodiline (DB13725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terodiline hydrochloride 12 mg once a day for 4 weeks
Study: 27016217
Drug: Flotation-REST treatment
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flotation-REST treatment (12 sessions)
Study: 24608453
Drug: Sulfasalazine with
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfasalazine with temozolomide and radiation therapy
Study: 24608453
Drug: Temozolomide and
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide and radiation therapy (Control)
Study: 23478632
Drug: Daily Disposable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Disposable (DD) contact lenses
Study: 23478632
Drug: Daily Wear
Normalized name: ZINC OXIDE 22.7 g in 100 g TOPICAL LOTION [ETHICAL ZINC DAILY WEAR LIGHT SUNSCREEN SPF-50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Wear with Hydrogen Peroxide (DW-H2O2)
Study: 23478632
Drug: Daily Wear
Normalized name: ZINC OXIDE 22.7 g in 100 g TOPICAL LOTION [ETHICAL ZINC DAILY WEAR LIGHT SUNSCREEN SPF-50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Wear with Multipurpose Solutions (DW-MPS)
Study: 16020461
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of food intake and exercise
Study: 12559641
Drug: Combined lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined lung cancer prevention agent (specifics not provided)
Study: 9858113
Drug: Cortisol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (200 mg/day)
Study: 7596966
Drug: State Modulation
Normalized name: CLOZAPINE (GOLDEN STATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: State Modulation (SM) treatment
Study: 2187001
Drug: Theophylline treatment
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline treatment (two different dosage regimens)
Study: 9037573
Drug: Domperidone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (30 mg/day)
Study: 382149
Drug: Domperidone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (30 mg/day) during open phase
Study: 27475087
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of dasatinib once daily
Study: 27475087
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg of dasatinib twice daily
Study: 25129979
Drug: Intramuscular NGF
Normalized name: Panthenol 1 g in 100 mL TOPICAL SOLUTION [NGF 574H HAIR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular NGF treatment
Study: 25129979
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (intravenous vasodilators, energy mixture, steroid pulse therapy, methylcobalamin neurotrophic therapy)
Study: 18949181
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii (500 mg/day) for 12 days
Study: 15843667
Drug: Gatifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin (400 mg daily for 2 weeks, then 10-day course every month for 2 years)
Study: 10351964
Drug: Abciximab (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abciximab (bolus 0.25 mg/kg and 12-hour infusion of 0.125 microg/kg/min)
Study: 10351964
Drug: Accelerated-dose alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Accelerated-dose alteplase (100 mg)
Study: 10351964
Drug: Alteplase (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase (50 mg, 15 mg bolus; infusion of 35 mg over 60 minutes) plus abciximab
Study: 10351964
Drug: Alteplase (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase (50 mg, 15 mg bolus; infusion of 35 mg over 60 minutes) plus abciximab and low-dose heparin
Study: 10351964
Drug: Alteplase (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase (50 mg, 15 mg bolus; infusion of 35 mg over 60 minutes) plus abciximab and very-low-dose heparin
Study: 8824651
Drug: Psyllium (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium (5 g b.d.)
Study: 2117517
Drug: Levonorgestrel (L‐Ng,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel (L‐Ng, 0.03 mg twice a day for 20 days)
Study: 2117517
Drug: Ethinylestradiol (EE,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinylestradiol (EE, 0.05 mg per day for 20 days)
Study: 2117517
Drug: Ibuprofen (Ib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (Ib, 800 mg three times a day for 5 days)
Study: 2117517
Drug: Placebo (PL,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL, one pill of lactose for 20 days)
Study: 7352687
Drug: Epinephrine 0.1
Normalized name: epinephrine 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine 0.1 mg
Study: 7352687
Drug: Epinephrine 0.1
Normalized name: epinephrine 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine 0.1 mg (repeated administration)
Study: 30939422
Drug: Sugammadex (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex (Group S, n = 40) - 2 mg/kg
Study: 30939422
Drug: Neostigmine (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (Group N, n = 44) - 1 mg neostigmine methylsulfate and 0.2 mg glycopyrrolate
Study: 26091743
Drug: Evidence-based training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based training on providing counselling and insertion of IUDs or progestin implants
Study: 20137622
Drug: Transurethral electro-resection
Normalized name: ELECTRODE SPRAY,ELECTRO MIST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transurethral electro-resection or electric coagulation combined with bladder instillation of anti-tumor drugs (control group)
Study: 15339759
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for stress urinary incontinence
Study: 15056514
Drug: Risperidone (0.02-0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (0.02-0.06 mg/kg/day, mean dose 1.5 mg/day)
Study: 11822756
Drug: Topotecan and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan and Etoposide (dose level 3: T/E 1.00/100 mg/m2 and 75 mg/m2 respectively)
Study: 1177348
Drug: Co-trimoxazole (trimethoprim/sulphamethoxazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (trimethoprim/sulphamethoxazole, 10 mg trimethoprim/kg/day in two divided daily doses for 10 days)
Study: 1177348
Drug: Chloramphenicol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol (100 mg/kg/day in four divided daily doses for 10 days)
Study: 25372657
Drug: Problem adaptation
Normalized name: Psoriasin Problem Skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem adaptation therapy (PATH)
Study: 25372657
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy for cognitively impaired patients (ST‐CI)
Study: 27654854
Drug: Tolvaptan (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan (30 mg)
Study: 1456569
Drug: Furosemide (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (80 mg)
Study: 1727581
Drug: Intrauterine PGF2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine PGF2 alpha infusion (20 mg diluted in 500 mL NaCl 0.9%)
Study: 1727581
Drug: IV oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV oxytocin infusion (increasing doses)
Study: 26890999
Drug: Adolescent Coping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adolescent Coping With Depression Course and Functional Family Therapy for SUD (depression treatment followed by SUD treatment)
Study: 26890999
Drug: Adolescent Coping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adolescent Coping With Depression Course and Functional Family Therapy for SUD (SUD treatment followed by depression treatment)
Study: 26890999
Drug: Adolescent Coping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adolescent Coping With Depression Course and Functional Family Therapy for SUD (coordinated treatment)
Study: 20404423
Drug: Allopurinol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (100 mg/d)
Study: 17692615
Drug: Fenoldopam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam (0.1 mg*kg‐1*min‐1)
Study: 17692615
Drug: Dopamine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine (3 mg*kg‐1*min‐1)
Study: 9785761
Drug: Exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise group (15 women) - daily outdoor walking and gymnastic training for 12 months
Study: 2744910
Drug: Carbocysteine (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbocysteine (4.5 g/day)
Study: 6113175
Drug: Lormetazepam (Noctamid)
Normalized name: lormetazepam Oral Tablet [Noctamid]
DrugBank: Lormetazepam (DB13872)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lormetazepam (Noctamid) 1 mg
Study: 6113175
Drug: Diazepam (Valium)
Normalized name: diazepam Oral Tablet [Valium]
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazepam (Valium) 5 mg
Study: 29765200
Drug: AZD1981 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1981 (400 mg BID)
Study: 29765200
Drug: AZD1981 (other
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1981 (other doses)
Study: 27391857
Drug: Gynura pseudochina
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gynura pseudochina DC. var. hispida Thv. ointment
Study: 27391857
Drug: 0.1% triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% triamcinolone (TA) cream
Study: 21257799
Drug: Roflumilast (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast (oral daily doses for 14 days)
Study: 21257799
Drug: Digoxin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (single oral dose on day 1)
Study: 19171611
Drug: School-based supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based supervised therapy
Study: 9613305
Drug: Low-dose regional
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose regional labour analgesia (bupivacaine and fentanyl)
Study: 7859894
Drug: Easiest mode
Approvals — FDA: no, EMA: no, PMDA: no
Description: Easiest mode of insulin injection
Study: 7859894
Drug: Two different
Normalized name: IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINEPROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY, BIPARATOPIC (TARGETING TWO DIFFERENT NON-OVERLAPP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two different forms of insulin delivery
Study: 31337414
Drug: Two-way texting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-way texting intervention (daily text messages with follow-up only if desired or if a complication is suspected)
Study: 24423419
Drug: Fospropofol (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fospropofol (initial dose of 6.5 mg/kg, supplemental doses of 1.6 mg/kg as needed)
Study: 24423419
Drug: Midazolam (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (initial dose of 0.05 mg/kg, supplemental doses of 0.02 mg/kg)
Study: 21412134
Drug: Dexamethasone (Dexacort,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (Dexacort, 20 mg)
Study: 19414694
Drug: DPTaP‐Hib vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPTaP‐Hib vaccine first
Study: 17846346
Drug: Plasma cardiotrophin-1
Normalized name: Cardiotrophin 1
DrugBank: Cardiotrophin 1 (DB18399)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma cardiotrophin-1 after 1 year of antihypertensive treatment
Study: 21663809
Drug: Lidocaine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (40 mg)
Study: 10876462
Drug: Propofol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (20 mg)
Study: 9179056
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose chlorambucil (HD-CLB)
Study: 1489115
Drug: Almitrine bismesylate
Normalized name: almitrine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine bismesylate (1 mg/kg over 1 h)
Study: 2951826
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ipratropium bromide (40 micrograms) and fenoterol (200 micrograms)
Study: 2951826
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ipratropium bromide and fenoterol
Study: 30112792
Drug: MYL-1501D and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MYL-1501D and Insulin glargine
Study: 21524790
Drug: Cercon control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cercon control (CC)
Study: 18065202
Drug: Soy isoflavone
Normalized name: soy isoflavone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavone 40 mg once a day for 6 months
Study: 18065202
Drug: Casein placebo
Normalized name: caseins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein placebo 40 mg once a day for 6 months
Study: 14556479
Drug: Intensive and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive and short duration chemotherapy (LMB protocols)
Study: 1906239
Drug: TAP-144-SR 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP-144-SR 3.75 mg administered subcutaneously at 4-week intervals for 12 weeks (total of 3 injections)
Study: 1906239
Drug: Diethylstilbestrol diphosphate
Normalized name: Diethylstilbestrol Diphosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylstilbestrol diphosphate 100 mg administered orally three times a day for 12 weeks
Study: 6125155
Drug: estazolam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: estazolam (2 mg)
Study: 29238169
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of flupirtine maleate capsule under fasting condition
Study: 29238169
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of flupirtine maleate capsule under fed condition
Study: 29238169
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of flupirtine maleate capsule under fasting condition
Study: 29238169
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of flupirtine maleate capsule under fed condition
Study: 27798030
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) plus usual care
Study: 24929624
Drug: sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sitagliptin 100 mg/day
Study: 22383949
Drug: N-acetyl-cysteine (NAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-cysteine (NAC) administered for 60 days followed by placebo for another 60 days
Study: 21158957
Drug: Healthy Foods
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy Foods North (HFN) programme; a multi-institutional and culturally appropriate intervention to improve dietary adequacy and reduce chronic disease risk; specific dosage and duration not available.
Study: 17685739
Drug: Piracetam (4800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (4800 mg/day)
Study: 2679938
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (health education promoting a cholesterol-lowering diet, smoking cessation, weight control, physical activity, treatment of arterial hypertension)
Study: 31248399
Drug: Oral presentation
Normalized name: Gas-X Prevention Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral presentation
Study: 30381311
Drug: Tadalafil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (20 mg once daily along with conventional management)
Study: 21275439
Drug: Armodafinil 50
Normalized name: armodafinil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil 50 mg on day 1, 100 mg on day 2, and 150 mg once daily on days 3 through 7
Study: 19892047
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of autologous mononuclear bone marrow stem cells (BMSCs)
Study: 11032279
Drug: Traditional antiemetic
Normalized name: metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional antiemetic agents (droperidol)
Study: 11032279
Drug: Traditional antiemetic
Normalized name: metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional antiemetic agents (metoclopramide)
Study: 9064405
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of drugs (group IM)
Study: 9064405
Drug: Multiple drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple drugs (60%)
Study: 1338319
Drug: D-F 15
Normalized name: Mite D.F.
DrugBank: Dermatophagoides farinae (DB10400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-F 15 mg b.d. for 26 weeks
Study: 8805113
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg acetaminophen
Study: 11510914
Drug: Standardized medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized medical treatment
Study: 26794722
Drug: Invasive strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive strategy (early coronary angiography with immediate assessment for percutaneous coronary intervention, coronary artery bypass graft, and optimum medical treatment)
Study: 26794722
Drug: Conservative strategy
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative strategy (optimum medical treatment alone)
Study: 24886352
Drug: Weekly 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly 1.5 hour weight management group until 6 weeks postpartum, combining Slimming World expertise with NHS midwives' clinical advice.
Study: 23181339
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration (WBV) intervention, conducted in a home-based setting, for six weeks, twice a week.
Study: 23181339
Drug: Placebo training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo training intervention, conducted in a home-based setting, for six weeks, after a two-week washout period, twice a week.
Study: 20103032
Drug: Energy drink
Normalized name: Boost Energy Drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy drink (250 mL, sugar-free)
Study: 17669707
Drug: Ultrasound-guided fine-needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided fine-needle aspiration (FNA) with measurement of parathyroid hormone (PTH) in the aspirate
Study: 10457875
Drug: Tramadol drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol drops 1.5 mg kg-1 (n = 31)
Study: 10432161
Drug: 72-hour intravenous
Normalized name: 72 Hour Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 72-hour intravenous tubing set changes
Study: 10432161
Drug: 24-hour intravenous
Normalized name: 24 Hour Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour intravenous tubing set changes
Study: 330480
Drug: 375 mg
Normalized name: niacin 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg amoxycillin three times daily
Study: 330480
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg pivmecillinam three times daily
Study: 330480
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg pivmecillinam three times daily
Study: 28257752
Drug: Idelalisib plus
Normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Idelalisib plus ofatumumab (oral idelalisib 150 mg twice daily continuously plus ofatumumab 300 mg intravenously in week 1, then 1000 mg intravenously weekly for 7 weeks, and every 4 weeks for 16 weeks)
Study: 28257752
Drug: Ofatumumab alone
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab alone (ofatumumab dosing as per the combination group, except 2000 mg was substituted for the 1000 mg dose)
Study: 25981401
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no tadalafil treatment)
Study: 19253237
Drug: Tafluprost 0.0015%
Normalized name: TAFLUPROST 0.0015% OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafluprost 0.0015% (once daily) with timolol 0.5% (twice daily)
Study: 19253237
Drug: Vehicle with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle with timolol 0.5% (twice daily)
Study: 9468460
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A (CsA; 10 mg/kg)
Study: 8560834
Drug: Indobufen 400
Normalized name: indobufen
DrugBank: Indobufen (DB12545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen 400 mg perorally, given one day prior to operation and continued daily for three months
Study: 8560834
Drug: Indobufen treatment
Normalized name: indobufen
DrugBank: Indobufen (DB12545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen treatment
Study: 2884190
Drug: Mifentidine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifentidine (10 mg)
Study: 26718605
Drug: IV delafloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV delafloxacin (300 mg)